More than 900 myeloma abstracts (posters and oral sessions) will be presented in the largest world congress of hematology: the American Society of Hematology (ASH) Annual Meeting 2019 that will be held from 7 to 10 December 2019 in Orlando, Florida, USA. Continue reading
It is with great sadness that we share that our friend, colleague and Board member Lisa Kotschi passed away in the night of the 21st November 2019. Continue reading
Myeloma Patients Europe (MPE) is holding another round of Myeloma Community Advisory Board (Myeloma-CAB) meetings from 17 – 18 November in Munich, Germany. The Myeloma-CAB focuses on providing patient perspectives and advice on clinical development in myeloma, challenges in access to myeloma medicines and patient engagement in myeloma research and development. These meeting ensure meaningful and systematic engagement with the patient community in Europe. Continue reading
The randomized, placebo-controlled, double-blind Phase 3 clinical trial TOURMALINE-MM4 showed significant improvement in Progression-Free Survival (PFS) of Ixazomib (commercialised by Takeda as Ninlaro) as first line maintenance therapy versus placebo in adult myeloma patients not treated with stem cell transplantation. This clinical trial is the first industry sponsored phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not included in initial induction therapy, in this setting. Continue reading
The professional society for health economics and outcomes research, ISPOR, organises its annual meeting in Copenhagen, Denmark. From 2 to 6 November experts attending this meeting will debate value in healthcare beyond cost-containment and short-term interventions. Continue reading
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the drug daratumumab (Darzalex®, commercialised by Janssen). Continue reading
The European Society for Medical Oncology (ESMO) Annual Congress was held from 27 September to 1 October 2019 in Barcelona, Spain. Continue reading
More than 3.900 abstracts have been submitted to the European Society for Medical Oncology Congress (ESMO) Annual Congress which will be held from 27 September to 1st October 2019 in Barcelona, Spain. Continue reading
More than 3.900 abstracts have been submitted to the European Society for Medical Oncology Congress (ESMO) Annual Congress which will be held from 27 September to 1st October 2019 in Barcelona, Spain. Continue reading
Led by International Myeloma Society (IMS), the 17th International Myeloma Workshop (IMW) will be held in Boston, USA, from 12 to 15 September. During the Workshop the latest breakthroughs in myeloma and related diseases will be presented and analysed by leading doctors, researchers and patient advocates in the community. Continue reading